Radiofrequency ablation of pancreatic neuroendocrine tumors: A pilot study of feasibility, efficacy, and safety

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: This study aimed to assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) of pancreatic neuroendocrine tumors (PNETs). Methods: We performed RFA on 10 patients (7 women) aged 38 to 75 years with histologically diagnosed PNETs (secreting in 3 cases) who could not or would not undergo surgical resection. Tumor nodules (diameter, 0.9-2.9 cm; mean [SD], 1.6 [0.5] cm) were located in the head (n = 7) or body (n = 3) of the pancreas. Ultrasound-guided RFA was performed percutaneously (n = 7), endoscopically (n = 1), or intraoperatively (n = 2) using commercially available equipment. Complete ablation was defined as absence of enhancing tissue at the tumor site on contrast-enhanced imaging studies and normalization of previously elevated serum hormone levels. Results: Complete ablation was achieved with 1 (n = 9) or 2 (n = 1) RFA procedures. All neuroendocrine syndromes regressed within 24 hours of treatment. No recurrences were observed during follow-up (range, 12-60 months; median [SD], 34 [14] months). No deaths occurred. Major complications included acute pancreatitis in 3 patients, 2 of whom developed pancreatic fluid collections that were successfully managed with ultrasound-guided drainage and endoscopy. Conclusions: Radiofrequency ablation is a feasible, safe, and effective option for patients with small PNETs who cannot or do not want to undergo surgical resection.

Original languageEnglish
Pages (from-to)938-945
Number of pages8
JournalPancreas
Volume43
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Neuroendocrine Tumors
Safety
Pancreatitis
Endoscopy
Drainage
Pancreas
Neoplasms
Head
Hormones
Recurrence
Equipment and Supplies
Serum
Therapeutics

Keywords

  • echoendoscopy
  • minimally invasive therapy
  • neuroendocrine pancreatic tumors
  • Pancreatic cancer
  • radiofrequency ablation
  • ultrasonography

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

@article{5b2610a6106145dab1f7cd37f3624016,
title = "Radiofrequency ablation of pancreatic neuroendocrine tumors: A pilot study of feasibility, efficacy, and safety",
abstract = "Objective: This study aimed to assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) of pancreatic neuroendocrine tumors (PNETs). Methods: We performed RFA on 10 patients (7 women) aged 38 to 75 years with histologically diagnosed PNETs (secreting in 3 cases) who could not or would not undergo surgical resection. Tumor nodules (diameter, 0.9-2.9 cm; mean [SD], 1.6 [0.5] cm) were located in the head (n = 7) or body (n = 3) of the pancreas. Ultrasound-guided RFA was performed percutaneously (n = 7), endoscopically (n = 1), or intraoperatively (n = 2) using commercially available equipment. Complete ablation was defined as absence of enhancing tissue at the tumor site on contrast-enhanced imaging studies and normalization of previously elevated serum hormone levels. Results: Complete ablation was achieved with 1 (n = 9) or 2 (n = 1) RFA procedures. All neuroendocrine syndromes regressed within 24 hours of treatment. No recurrences were observed during follow-up (range, 12-60 months; median [SD], 34 [14] months). No deaths occurred. Major complications included acute pancreatitis in 3 patients, 2 of whom developed pancreatic fluid collections that were successfully managed with ultrasound-guided drainage and endoscopy. Conclusions: Radiofrequency ablation is a feasible, safe, and effective option for patients with small PNETs who cannot or do not want to undergo surgical resection.",
keywords = "echoendoscopy, minimally invasive therapy, neuroendocrine pancreatic tumors, Pancreatic cancer, radiofrequency ablation, ultrasonography",
author = "Sandro Rossi and Viera, {Francesca Torello} and Giorgia Ghittoni and Lorenzo Cobianchi and Rosa, {Laura Lavinia} and Luisa Siciliani and Chandra Bortolotto and Letizia Veronese and Alessandro Vercelli and Anna Gallotti and Valentina Ravetta",
year = "2014",
doi = "10.1097/MPA.0000000000000133",
language = "English",
volume = "43",
pages = "938--945",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Radiofrequency ablation of pancreatic neuroendocrine tumors

T2 - A pilot study of feasibility, efficacy, and safety

AU - Rossi, Sandro

AU - Viera, Francesca Torello

AU - Ghittoni, Giorgia

AU - Cobianchi, Lorenzo

AU - Rosa, Laura Lavinia

AU - Siciliani, Luisa

AU - Bortolotto, Chandra

AU - Veronese, Letizia

AU - Vercelli, Alessandro

AU - Gallotti, Anna

AU - Ravetta, Valentina

PY - 2014

Y1 - 2014

N2 - Objective: This study aimed to assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) of pancreatic neuroendocrine tumors (PNETs). Methods: We performed RFA on 10 patients (7 women) aged 38 to 75 years with histologically diagnosed PNETs (secreting in 3 cases) who could not or would not undergo surgical resection. Tumor nodules (diameter, 0.9-2.9 cm; mean [SD], 1.6 [0.5] cm) were located in the head (n = 7) or body (n = 3) of the pancreas. Ultrasound-guided RFA was performed percutaneously (n = 7), endoscopically (n = 1), or intraoperatively (n = 2) using commercially available equipment. Complete ablation was defined as absence of enhancing tissue at the tumor site on contrast-enhanced imaging studies and normalization of previously elevated serum hormone levels. Results: Complete ablation was achieved with 1 (n = 9) or 2 (n = 1) RFA procedures. All neuroendocrine syndromes regressed within 24 hours of treatment. No recurrences were observed during follow-up (range, 12-60 months; median [SD], 34 [14] months). No deaths occurred. Major complications included acute pancreatitis in 3 patients, 2 of whom developed pancreatic fluid collections that were successfully managed with ultrasound-guided drainage and endoscopy. Conclusions: Radiofrequency ablation is a feasible, safe, and effective option for patients with small PNETs who cannot or do not want to undergo surgical resection.

AB - Objective: This study aimed to assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) of pancreatic neuroendocrine tumors (PNETs). Methods: We performed RFA on 10 patients (7 women) aged 38 to 75 years with histologically diagnosed PNETs (secreting in 3 cases) who could not or would not undergo surgical resection. Tumor nodules (diameter, 0.9-2.9 cm; mean [SD], 1.6 [0.5] cm) were located in the head (n = 7) or body (n = 3) of the pancreas. Ultrasound-guided RFA was performed percutaneously (n = 7), endoscopically (n = 1), or intraoperatively (n = 2) using commercially available equipment. Complete ablation was defined as absence of enhancing tissue at the tumor site on contrast-enhanced imaging studies and normalization of previously elevated serum hormone levels. Results: Complete ablation was achieved with 1 (n = 9) or 2 (n = 1) RFA procedures. All neuroendocrine syndromes regressed within 24 hours of treatment. No recurrences were observed during follow-up (range, 12-60 months; median [SD], 34 [14] months). No deaths occurred. Major complications included acute pancreatitis in 3 patients, 2 of whom developed pancreatic fluid collections that were successfully managed with ultrasound-guided drainage and endoscopy. Conclusions: Radiofrequency ablation is a feasible, safe, and effective option for patients with small PNETs who cannot or do not want to undergo surgical resection.

KW - echoendoscopy

KW - minimally invasive therapy

KW - neuroendocrine pancreatic tumors

KW - Pancreatic cancer

KW - radiofrequency ablation

KW - ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=84904397715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904397715&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000133

DO - 10.1097/MPA.0000000000000133

M3 - Article

C2 - 24717825

AN - SCOPUS:84904397715

VL - 43

SP - 938

EP - 945

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 6

ER -